Autosomal Recessive Spinocerebellar Ataxia 20 (SCAR20)

Autosomal Recessive Spinocerebellar Ataxia 20 (SCAR20) is a very rare, inherited brain disorder that starts in infancy or early childhood. Children have trouble with balance and coordination (ataxia) because the cerebellum (the brain’s balance center) is smaller or wastes away (cerebellar atrophy) on MRI. Most children also have developmental delay, little or no speech, and intellectual disability. Many have coarsened facial features, sometimes relative macrocephaly (a head that looks large for body size), and a few have seizures, hearing loss, or skeletal features. The condition happens when a child inherits two non-working copies of a gene called SNX14 (one from each parent). SNX14 helps cells handle fats and recycle worn-out parts; without it, brain cells—especially Purkinje cells in the cerebellum—do not work well and slowly degenerate. NCBI+2Frontiers+2

SCAR20 is a rare, inherited brain condition that starts in infancy or early childhood. It happens when both copies of the SNX14 gene are changed (mutated). Children develop poor balance and coordination (ataxia), delayed development and speech, often a wide-based or absent walk, and progressive shrinking of the cerebellum on brain scans. Other common features include coarse facial appearance, intellectual disability, and sometimes hearing loss or skeletal differences. There is no cure yet; care focuses on therapy, safety, and symptom control. PMC+2NCBI+2

Important: SCAR20 (autosomal recessive) is not the same as SCA20 (autosomal dominant). SCA20 is an adult-onset ataxia with different genetics and symptoms. This article is about SCAR20. MalaCards

Other names

• SNX14-related disorder

• SNX14-associated autosomal recessive cerebellar ataxia

• Intellectual disability–coarse face–macrocephaly–cerebellar atrophy syndrome (Orphanet label)

• Autosomal recessive spinocerebellar ataxia-20; SCAR20
  These names all refer to the same condition caused by SNX14 gene variants. Orpha+1

SNX14 is a sorting nexin protein that sits on the endoplasmic reticulum and works at contact sites with lipid droplets and lysosomes. It helps cells manage fats (lipids), move cargo inside the cell, and recycle damaged parts (autophagy/lysosomal pathway). When SNX14 does not work, lipid homeostasis breaks down, mitochondria do not travel normally along Purkinje cell axons, and these sensitive cerebellar neurons become sick and are lost over time—leading to ataxia and cerebellar atrophy. JCI Insight+3OUP Academic+3PNAS+3

Types

Doctors do not split SCAR20 into formal subtypes, but the medical literature shows a spectrum:

1. Classic early-onset SCAR20 – infancy/early childhood onset; developmental delay, absent or very limited speech, cerebellar atrophy, coarse facial features; often the most severe. NCBI

2. Childhood-onset with mixed features – early motor delay and ataxia plus variable features such as seizures, hearing loss, or autism traits; still with clear cerebellar atrophy. PMC+1

3. Milder childhood presentation – later milestones but some speech, milder intellectual disability; MRI still shows cerebellar atrophy; very rare. (This reflects the variability reported across families.) Frontiers

Causes

1. Biallelic loss-of-function SNX14 variants – the core cause: two damaging changes stop the protein from working. OUP Academic

2. Homozygous nonsense/frameshift variants – create a truncated, non-functional protein. OUP Academic

3. Splice-site or deep intronic variants – mis-splicing removes key parts of the message; recently reported cases highlight this. Frontiers

4. Compound heterozygosity – two different harmful variants, one on each parental copy. Frontiers

5. Missense variants in functional domains – single-letter changes that harm the PX or related domains and derail targeting or binding. OUP Academic

6. Disrupted endolysosomal trafficking – cargo can’t be sorted or recycled properly, stressing neurons. OUP Academic

7. Impaired autophagy-lysosome function – worn-out cell parts accumulate and injure neurons. PMC

8. Lipid droplet–ER tethering defects – poor handling of neutral lipids at contact sites. PNAS

9. Global lipid homeostasis imbalance – toxic lipid build-up or mis-distribution in the brain. JCI Insight

10. Purkinje cell mitochondrial transport failure – energy supply within cerebellar axons breaks down. OUP Academic

11. Developmental vulnerability of cerebellum – the developing cerebellum is highly sensitive to SNX14 loss. Nature

12. Neuroinflammation secondary to cell stress – likely downstream of trafficking and lipid defects (inferred from related models). JCI Insight

13. Synaptic dysfunction – altered membrane trafficking can disturb synapse maintenance. OUP Academic

14. Axonal transport slowdown – beyond mitochondria, general cargo movement can falter. OUP Academic

15. Modifier genes – other common variants may shape how severe symptoms become (general principle in rare ataxias). SciELO

16. Environmental stressors – fever, illness, or sedation may temporarily worsen coordination (typical in cerebellar disorders). SciELO

17. Nutritional imbalance – does not cause SCAR20 but can aggravate function in children with neurological disability; correcting it helps care. (General pediatric neurology practice.) SciELO

18. Seizures – if present, seizures can worsen learning and motor control unless treated. (Reported in some SCAR20 cohorts.) Nature

19. Hearing loss – if unrecognized, it worsens speech outcomes in affected children. PMC

20. Delayed diagnosis – late access to therapies and supports increases disability load, even though it does not change genetics. (Observed across rare ataxias.) SciELO

Common signs and symptoms

1. Ataxia – unsteady, wide-based gait; clumsy reach; frequent falls. This is the most visible sign. NCBI

2. Cerebellar atrophy (seen on MRI) – the cerebellum is smaller than expected for age. NCBI

3. Developmental delay – motor and language milestones arrive late. NCBI

4. Little or no speech – many children remain minimally verbal. NCBI

5. Intellectual disability – learning and problem-solving are affected. NCBI

6. Coarse facial features – broad nasal bridge, full lips, or other subtle facial traits that become more obvious with age. PMC

7. Relative macrocephaly – head size that looks large compared with body size in some patients. Frontiers

8. Hypotonia – low muscle tone in infancy; later, tone may be mixed. NCBI

9. Dysarthria – slurred or poorly coordinated speech when speech is present. NCBI

10. Oculomotor problems – trouble with smooth pursuit or saccades; sometimes strabismus. (General in cerebellar ataxias; reported variably.) SciELO

11. Seizures – present in a subset of children. Nature

12. Hearing loss – reported frequently in recent series; screening is important. PMC

13. Autism spectrum traits – social communication differences and repetitive behaviors in some. Frontiers

14. Feeding difficulties – poor coordination of chewing/swallowing can occur. (Common in early-onset cerebellar disorders.) SciELO

15. Skeletal features – such as minor anomalies or short stature in some families. Frontiers

Diagnostic tests

A) Physical examination

1. Neurologic exam focused on gait and coordination – doctors watch walking, stance, and rapid alternating movements; the pattern points to cerebellar ataxia. SciELO

2. Tone and reflex check – low tone in infancy; reflexes help rule in/out other neurologic problems that can mimic ataxia. SciELO

3. Cranial-nerve and eye-movement exam – looks for nystagmus, saccade slowing, or pursuit problems typical of cerebellar disease. SciELO

4. Dysmorphology assessment – documents coarse facial features and body proportions (e.g., relative macrocephaly). Frontiers

5. Hearing and speech screening in clinic – early clues to hearing loss and dysarthria, which affect therapy plans. PMC

B) Bedside/manual coordination tests

6. Finger-to-nose testing – shows intention tremor and dysmetria. SciELO

7. Heel-to-shin testing – checks lower-limb coordination. SciELO

8. Rapid alternating movements (diadochokinesia) – difficulty switching fast between movements is typical of cerebellar dysfunction. SciELO

9. Tandem gait and Romberg – unsteady, wide-based steps and sway with eyes closed support a cerebellar pattern (while also helping exclude pure sensory ataxia). SciELO

10. Oculomotor bedside tests – saccades, pursuit, and fixation to capture subtle cerebellar eye findings. SciELO

C) Laboratory and pathological tests

11. Genetic testing (SNX14 sequencing or exome/genome) – confirms two pathogenic SNX14 variants; this is the definitive test. Frontiers

12. Copy-number/splice-aware analysis – to detect exonic deletions/duplications or deep intronic splice defects that standard panels may miss. Frontiers

13. Metabolic screens – serum amino/organic acids, lactate, very-long-chain fatty acids, etc., to exclude mimics; SCAR20 itself is not a primary metabolic disease, but these tests prevent misdiagnosis. SciELO

14. Clinical labs for nutrition and thyroid – identify treatable factors that worsen function (iron, B12, vitamin D, thyroid). (General pediatric neurology care.) SciELO

15. Research/biopsy-based lipid studies (selected centers) – fibroblast lipid-droplet assays may show SNX14-related lipid handling defects; mainly research-use. PNAS

D) Electrodiagnostic tests

16. EEG – if seizures are suspected; guides antiseizure treatment. Nature

17. Brainstem auditory evoked responses (BAER) – objective hearing pathway test when behavioral audiology is hard. PMC

18. Nerve conduction/EMG (if neuropathy suspected) – helps rule out peripheral causes of imbalance or weakness in atypical cases. (General ataxia workup.) SciELO

E) Imaging tests

19. Brain MRI – key test: shows cerebellar atrophy (often global or vermian-predominant); helps distinguish from other causes. NCBI

20. MRI with volumetrics – when available, measures cerebellar volume to track progression over time. (Applied in cerebellar ataxia research/clinics.) GIM Journal

21. MR spectroscopy – may show metabolic changes in the cerebellum; supportive, not diagnostic. (General cerebellar ataxia practice.) GIM Journal

22. CT head (limited use) – less sensitive than MRI; used only if MRI is unavailable/contraindicated. (General neuroradiology practice.) SciELO

23. Spine MRI (selected cases) – rules out coincidental spinal causes of gait issues. (General workup.) SciELO

24. Audiology with objective tests – formal hearing evaluation to document sensorineural loss. PMC

25. Skeletal imaging when indicated – only if clinical exam suggests skeletal anomalies. Frontiers

Non-pharmacological treatments (therapies & others)

1. Specialized physical therapy (PT) for ataxia
   Purpose: Improve balance, walking, coordination, and daily function. Mechanism: Repeated, goal-directed balance and coordination training helps the brain “re-learn” movement patterns and use remaining cerebellar pathways more efficiently. Programs often mix gait, balance, strengthening, and endurance work. Evidence and consensus place PT as a mainstay of care for hereditary/degenerative ataxias. PubMed+2Frontiers+2

2. Occupational therapy (OT)
   Purpose: Maintain independence in dressing, eating, writing, and work/leisure. Mechanism: Task-specific practice, energy conservation, and adaptive strategies (e.g., weighted utensils, button hooks, writing grips) reduce the impact of tremor and incoordination on daily life. OT is a core pillar in ataxia management guidelines. PubMed+1

3. Speech-language therapy (SLT) for dysarthria and dysphagia
   Purpose: Clearer speech and safer swallowing. Mechanism: Breath support, rate control, and articulation drills can improve speech intelligibility; swallow exercises, postural adjustments, and diet texture changes lower choking and aspiration risk. Early SLT reduces complications. pn.bmj.com+1

4. Swallowing safety program & diet texture modification
   Purpose: Prevent aspiration pneumonia and weight loss when swallowing is weak or uncoordinated. Mechanism: Thickened liquids, small bites, chin-tuck, and supervised meals reduce airway entry; objective swallow studies guide changes. PMC+1

5. Assistive devices for mobility and safety
   Purpose: Reduce falls and injury. Mechanism: Ankle-foot orthoses, canes, walkers, and wheelchairs stabilize center of mass; home modifications (grab bars, non-slip mats, night lighting) lower fall risk. pn.bmj.com

6. Coordinative & balance-specific training (e.g., Frenkel-type, treadmill with support)
   Purpose: Target cerebellar motor learning. Mechanism: High-repetition, graded coordination drills improve smoothness and timing of limb and trunk movements; safety harnesses allow intensive practice without falls. Frontiers

7. Vision and hearing support
   Purpose: Optimize sensory input to compensate for ataxia. Mechanism: Corrective lenses, low-vision strategies, and timely fitting of hearing aids improve balance cues, communication, and learning. pn.bmj.com

8. Nutrition counseling & proactive hydration
   Purpose: Maintain weight, muscle mass, and energy; reduce constipation. Mechanism: Diets rich in protein, fiber, and fluids support rehab and reduce secondary complications; vitamin D and calcium protect bone health when activity is limited. Office of Dietary Supplements

9. Mental health care (anxiety/depression management)
   Purpose: Improve coping, adherence to rehab, and quality of life. Mechanism: Cognitive-behavioral strategies and caregiver support reduce stress load and fatigue associated with progressive disorders. pn.bmj.com

10. Fall-prevention & home safety evaluation
    Purpose: Reduce fractures and hospitalizations. Mechanism: PT/OT walk-throughs identify hazards; education plus device training lowers fall rate in progressive ataxias. pn.bmj.com

11. School/IEP support (for children)
    Purpose: Accessible learning and communication. Mechanism: Occupational, speech, and resource services embedded in school plans accommodate motor and language delays common in SCAR20. NCBI

12. Fatigue management / energy conservation
    Purpose: Extend activity time and participation. Mechanism: Pacing, scheduled rests, and prioritizing tasks reduce overexertion, which worsens ataxia temporarily. pn.bmj.com

13. Caregiver training
    Purpose: Safe transfers, feeding, communication, and exercise carryover at home. Mechanism: Skills training lowers complications and enhances therapy gains. pn.bmj.com

14. Orthotics & positioning for scoliosis/contracture risk
    Purpose: Maintain comfort and function. Mechanism: Seating systems, bracing, and night splints support posture and joint range in progressive neuromotor disorders. PMC

15. Respiratory hygiene when swallow is poor
    Purpose: Lower pneumonia risk. Mechanism: Cough techniques and secretion management reduce aspiration-related infections in neurogenic dysphagia. PMC

16. PEG feeding (when severe, persistent dysphagia)
    Purpose: Ensure nutrition/medication delivery and reduce aspiration in recurrent pneumonia. Mechanism: Direct stomach access bypasses unsafe swallowing; decision guided by a multidisciplinary team. PMC+1

17. Community and rare-disease support groups
    Purpose: Education, coping, and access to trials. Mechanism: Peer networks improve adherence and quality of life in progressive neurologic disease. pn.bmj.com

18. Advance care planning (progressive course)
    Purpose: Align care with family goals. Mechanism: Early discussions about mobility, feeding, and communication options reduce crisis decisions. pn.bmj.com

19. Genetic counseling for family planning
    Purpose: Explain recurrence risks and carrier testing. Mechanism: SCAR20 is autosomal recessive; counseling guides prenatal/early testing choices. Monarch Initiative

20. Regular multidisciplinary follow-up
    Purpose: Track swallowing, scoliosis, hearing, vision, and function. Mechanism: Team-based care (neuro, rehab, nutrition, ENT/ophthalmology) catches complications early. pn.bmj.com

---

Drug treatments

For each medicine below I cite its FDA label on accessdata.fda.gov. Doses shown are from the label for approved indications, not for SCAR20; clinicians individualize and adjust. Always evaluate interactions and contraindications.

1. Baclofen (oral) – spasticity/tone
   Typical label dosing 5–20 mg up to 3–4×/day; watch sedation and weakness. Mechanism: GABA_B agonist reduces spinal reflexes → less spasticity and cramps; can aid comfort, transfers, and care. (Off-label for ataxia-related tone.) FDA Access Data

2. Tizanidine – spasticity
   Label: start low (e.g., 2 mg), titrate; monitor hypotension and liver tests. Mechanism: α2-adrenergic agonist decreases polysynaptic spinal excitation. (Off-label for hereditary ataxia spasticity.) FDA Access Data

3. Clonazepam – myoclonus/tremor, anxiety
   Label warns about sedation, dependence. Mechanism: GABAergic enhancement calms hyperexcitable circuits, reducing jerks/tremor that worsen coordination. FDA Access Data

4. Gabapentin – neuropathic pain, myoclonus adjunct
   Label dosing commonly 300–1200 mg TID (per indication); adjust in renal disease. Mechanism: α2δ calcium-channel modulation dampens abnormal firing. FDA Access Data

5. Pregabalin – neuropathic pain/anxiety adjunct
   Label (e.g., 75–150 mg BID and titrate); monitor dizziness/edema. Mechanism: α2δ binding decreases synaptic release of excitatory transmitters, easing pain and some tremor. FDA Access Data

6. Amantadine – fatigue, dyskinesia-like movements
   Label cautions about livedo reticularis and confusion. Mechanism: dopaminergic and NMDA effects may reduce fatigue and abnormal movements in some patients. FDA Access Data

7. Propranolol – action tremor
   Label covers dosing ranges and contraindications (asthma, bradycardia). Mechanism: peripheral β-blockade dampens tremor amplitude, improving feeding/writing. FDA Access Data

8. Primidone – tremor
   Label provides barbiturate-related cautions; start low to minimize sedation/ataxia. Mechanism: GABAergic metabolite (phenobarbital) suppresses tremor generators. FDA Access Data

9. Topiramate – tremor/headache adjunct
   Label: titrate slowly; watch cognitive slowing, paresthesias. Mechanism: GABA-A modulation and sodium channel effects can lessen tremor/seizure co-morbidities. FDA Access Data

10. Acetazolamide – nystagmus/episodic ataxia features
    Label: diuretic-carbonic anhydrase inhibitor; watch electrolytes and kidney stones. Mechanism: Cerebellar membrane stabilization can reduce downbeat nystagmus/episodic spells in select patients (off-label in hereditary ataxias). FDA Access Data

11. Riluzole – off-label trials in ataxia
    Label: monitor liver injury. Mechanism: glutamatergic modulation; small studies explored gait/speech effects in degenerative ataxias, but no SCAR20 approval. FDA Access Data

12. Dalfampridine (4-AP ER) – gait speed (MS-approved)
    Label: 10 mg BID; seizure risk increases with higher doses/renal impairment. Mechanism: Potassium-channel block enhances conduction in demyelinated pathways; occasionally tried off-label for downbeat nystagmus/ataxia but not approved. FDA Access Data

13. Levodopa/carbidopa – parkinsonism features
    Label details titration; may help superimposed rigidity/bradykinesia if present. Mechanism: dopamine replacement for co-existing basal ganglia symptoms, not core SCAR20 ataxia. FDA Access Data

14. OnabotulinumtoxinA (Botox) – focal spasticity/sialorrhea
    Label covers dosing units and distribution; effects last ~3 months. Mechanism: presynaptic ACh block reduces focal hypertonia and drooling burden. FDA Access Data

15. Glycopyrrolate – excessive drooling (sialorrhea)
    Label (Robinul/Robinul Forte/Cuvposa) details anticholinergic dosing, cautions (constipation, urinary retention). Mechanism: reduces salivary secretion to improve hygiene and aspiration risk. FDA Access Data+1

16. Sertraline (SSRI) – depression/anxiety
    Label includes boxed warning for suicidality; improves mood and participation in rehab. Mechanism: serotonin reuptake inhibition. FDA Access Data

17. Modafinil – daytime sleepiness/fatigue
    Label warns about rash and psychiatric effects. Mechanism: promotes wakefulness and sustained attention, aiding therapy engagement. FDA Access Data

18. Pregabalin CR (extended-release) – neuropathic pain schedule simplification
    Label indicates once-daily dosing options for approved pain indications; off-label symptom control similar to IR. FDA Access Data

19. Droxidopa – neurogenic orthostatic hypotension (if present)
    Label: start 100 mg TID; monitor supine hypertension. Mechanism: norepinephrine prodrug improves standing blood pressure, reducing dizziness/falls. FDA Access Data

20. Midodrine – orthostatic hypotension alternative
    Label: 10 mg TID typical; boxed warnings for supine hypertension. Mechanism: α1-agonist increases vascular tone to support standing BP. FDA Access Data

Important: No drug above is FDA-approved to treat SCAR20 itself. They are used symptomatically, often off-label in hereditary ataxias; dosing must be individualized by a specialist. PMC

---

Dietary molecular supplements

Evidence for supplements in hereditary ataxias is limited. Use only under clinician guidance, especially with multiple medicines.

1. Coenzyme Q10 (CoQ10 / ubiquinone) – 100–300 mg/day commonly used
   Function/Mechanism: Supports mitochondrial energy production (electron transport). Small studies and case reports in some ataxias suggest benefit, especially in primary CoQ10 deficiency; evidence in SCAR20 is lacking. Watch interactions with anticoagulants. NCCIH+1

2. Vitamin E (alpha-tocopherol) – dose individualized; avoid excess
   Function/Mechanism: Fat-soluble antioxidant protecting cell membranes; proven in ataxia with vitamin-E deficiency, but not SCAR20. High doses may increase bleeding risk; respect ULs. Office of Dietary Supplements

3. Vitamin D – per lab-guided replacement
   Function/Mechanism: Bone and muscle health; supports fall prevention via bone strength and proximal muscle function; avoid toxicity with monitoring. Office of Dietary Supplements

4. Omega-3 fatty acids (EPA/DHA) – diet or capsules per clinician
   Function/Mechanism: Membrane function and anti-inflammatory effects; cardiovascular and general health support in chronic disability. Office of Dietary Supplements

5. Magnesium – dose guided by diet/renal function
   Function/Mechanism: Cofactor in >300 enzymes including those in nerve and muscle; may ease cramps/constipation. Excess can cause diarrhea; caution in kidney disease. Office of Dietary Supplements

6. Thiamine (Vitamin B1) – correct deficiency when present
   Function/Mechanism: Energy metabolism in neurons; deficiency causes neuropathy/ataxia. Supplement only if low or at risk. Office of Dietary Supplements

7. Creatine – individualized dosing if used
   Function/Mechanism: Phosphocreatine energy buffer for muscle work; may help short bursts of effort during rehab; evidence in neurologic disease is mixed. Office of Dietary Supplements

8. Alpha-lipoic acid – clinician-supervised
   Function/Mechanism: Redox cofactor/antioxidant explored in neuropathy and metabolism; monitor for hypoglycemia in diabetics. Office of Dietary Supplements

9. N-acetylcysteine (NAC) – consider only with guidance
   Function/Mechanism: Glutathione precursor with antioxidant effects; evidence in hereditary ataxias is limited; drug–supplement interactions possible. Office of Dietary Supplements

10. Turmeric/Curcumin – culinary use preferred; supplements cautiously
    Function/Mechanism: Anti-inflammatory/antioxidant actions; human evidence is heterogeneous; potential drug interactions (e.g., anticoagulants). Prefer food-based intake. NCCIH+1

---

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved immune-boosting, regenerative, or stem-cell therapies for SCAR20 (or for degenerative cerebellar ataxias generally). Patients should avoid clinics selling unapproved “stem-cell cures.” The FDA warns these can be unsafe and illegal. Below are concepts you may hear about; they are investigational/not approved for SCAR20:

1. Autologous or allogeneic stem-cell infusions: Not FDA-approved for neurologic diseases; associated with safety risks in unregulated settings. U.S. Food and Drug Administration+1

2. MSC (mesenchymal) products/exosomes: Heavily marketed but unapproved; FDA has issued warnings and enforcement actions. U.S. Food and Drug Administration

3. Gene therapy for hereditary ataxias: Active research exists, but no approved gene therapy for SCAR20. SpringerLink

4. Neurotrophic factors/biologics: Experimental; not approved for cerebellar degeneration. PMC

5. IVIG/steroids: Reserved for immune-mediated ataxias, which SCAR20 is not; can help those specific conditions when antibodies or immune triggers are present. Practical Neurology

6. Clinical trials participation: The safest way to access investigational approaches. Families should discuss registries and trials with their neurologist. pn.bmj.com

---

Surgeries/Procedures

1. Intrathecal baclofen (ITB) pump for severe, generalized spasticity interfering with care/mobility
   Procedure: Screening dose → pump implantation → programmable infusions. Why: When oral baclofen is ineffective or causes side effects, ITB delivers drug to spinal fluid for stronger tone control with lower systemic levels. FDA Access Data

2. Percutaneous endoscopic gastrostomy (PEG) for persistent unsafe swallowing/weight loss
   Procedure: Endoscopic tube placement into stomach. Why: Secures nutrition, hydration, and medication delivery; may reduce pneumonia in recurrent aspirators. PMC

3. Spinal fusion for progressive neuromuscular scoliosis (selected cases)
   Procedure: Instrumentation and fusion to correct/stop curve progression. Why: Improve sitting balance, comfort, and skin care when curves progress despite conservative measures. Children’s Hospital of Philadelphia+1

4. Tendon lengthening/transfer for fixed contractures severely limiting care or bracing
   Procedure: Orthopedic release or transfer of tight tendons. Why: Improve joint range, hygiene, and brace fit in carefully selected patients. ScienceDirect

5. Selective dorsal rhizotomy (rarely, highly selected)
   Procedure: Sectioning a proportion of sensory rootlets to reduce spasticity. Why: Considered only after multidisciplinary evaluation; aims to lower refractory spasticity and ease care. PubMed

---

Preventions

1. Genetic counseling for future pregnancies and relatives. Monarch Initiative

2. Routine rehab follow-up to adjust PT/OT/SLT plans as needs change. PubMed

3. Home fall-proofing (lighting, rails, remove loose rugs). pn.bmj.com

4. Vaccinations (influenza, pneumococcal) to reduce pneumonia risk in dysphagia. PMC

5. Bone health (vitamin D/calcium, weight-bearing as able). Office of Dietary Supplements

6. Oral care and drooling management to cut aspiration and skin issues. FDA Access Data

7. Hearing/vision checks to maximize sensory compensation. pn.bmj.com

8. Sleep hygiene to combat fatigue and falls. pn.bmj.com

9. Avoid alcohol/sedative overuse that worsens coordination. pn.bmj.com

10. Nutrition and hydration plans to prevent weight loss and constipation. Office of Dietary Supplements

---

When to see doctors (red flags)

See your neurologist promptly for: choking or recurrent chest infections; fast weight loss; frequent falls or new injuries; new or worsening scoliosis/contractures; fainting or severe dizziness on standing; sudden behavior or mood changes; or any drug side effect like severe sleepiness, confusion, rash, or liver issues (e.g., with riluzole). Ongoing scheduled visits help track progression and prevent crises. pn.bmj.com+1

---

What to eat” & “what to avoid

Eat more:

1. Protein + fiber each meal (eggs, fish/chicken/legumes + vegetables/whole grains) to maintain muscle and prevent constipation. Office of Dietary Supplements
2. Calcium + Vitamin D sources (dairy/fortified alternatives, safe sun per advice) for bone strength. Office of Dietary Supplements
3. Omega-3-rich foods (fatty fish, walnuts) for general cardiometabolic support. Office of Dietary Supplements
4. Fluids routinely to avoid dehydration-related dizziness. pn.bmj.com
5. Soft, moist textures if swallowing is difficult; follow SLT texture plan. PMC

Limit/avoid:

1. Alcohol and sedatives (worsen balance). pn.bmj.com
2. Very dry, crumbly, or stringy foods if dysphagia is present (choking risk). PMC
3. Excessive supplements without labs/medical advice (toxicity/interaction risk, e.g., high-dose vitamin E or curcumin with anticoagulants). Office of Dietary Supplements+1
4. High-sugar ultra-processed foods that crowd out nutrient-dense options (energy without strength). pn.bmj.com
5. Large meals before therapy if reflux/aspiration is an issue; use small, frequent meals. PMC

---

Frequently Asked Questions

1. Is there a cure for SCAR20?
   Not yet. Care focuses on therapies, safety, nutrition, and symptom-targeted medicines. PMC

2. Which gene is involved?
   SNX14; SCAR20 happens when both copies have harmful variants (autosomal recessive). NCBI

3. How is it diagnosed?
   By clinical features (early ataxia, cerebellar atrophy) plus genetic testing confirming SNX14 variants. PMC

4. Will therapy really help if the disease is progressive?
   Yes—PT/OT/SLT improve function, safety, and quality of life even when disease progresses. PubMed

5. Are there approved drugs for SCAR20 itself?
   No. Medicines are off-label for symptoms (spasticity, tremor, pain, mood, orthostatic dizziness). PMC

6. Is acetazolamide helpful?
   It may help certain nystagmus or episodic features in some ataxias; not a SCAR20 cure. FDA Access Data

7. Can stem-cell therapy cure SCAR20?
   No. FDA warns against unapproved stem-cell/exosome treatments for neurologic disorders. U.S. Food and Drug Administration

8. What about gene therapy?
   Research is ongoing for some ataxias; nothing approved for SCAR20 yet. SpringerLink

9. When is a feeding tube considered?
   If swallowing remains unsafe or weight loss persists despite therapy. PMC

10. What if there is severe spasticity?
    An intrathecal baclofen pump can be considered after a successful screening dose when oral meds fail. FDA Access Data

11. How can we reduce falls at home?
    Add rails/grab bars, improve lighting, use proper devices, and follow PT balance plans. pn.bmj.com

12. Should we take supplements?
    Only with clinician guidance; evidence is limited and some have risks or interactions. Office of Dietary Supplements+1

13. Do mood problems matter?
    Yes—treating depression/anxiety improves participation in rehab and overall outcomes. pn.bmj.com

14. Is SCAR20 the same as other SCAs?
    No—SCAR20 is recessive and SNX14-related with earlier neurodevelopmental features; many SCAs are dominant and adult-onset. NCBI

15. Can families get tested?
    Yes. Carrier and prenatal/early testing options exist through genetics clinics. Monarch Initiative

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 14, 2025.